# A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19

> **NCT04540185** · PHASE3 · UNKNOWN · sponsor: **Biomed Industries, Inc.** · enrollment: 3600 (estimated)

## Conditions studied

- Covid19
- SARS (Severe Acute Respiratory Syndrome)
- SARS-CoV Infection
- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** Biological: oral polio vaccine
- **BIOLOGICAL:** Comparable Placebo
- **DRUG:** NA-831
- **DRUG:** Comparable Placebo of drug
- **COMBINATION_PRODUCT:** Combination of oral polio vaccine and NA-831
- **COMBINATION_PRODUCT:** Comparable Placebo of Oral Polio Vaccine and Placebo of drug

## Key facts

- **NCT ID:** NCT04540185
- **Lead sponsor:** Biomed Industries, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-01
- **Primary completion:** 2022-11-01
- **Final completion:** 2022-12-31
- **Target enrollment:** 3600 (ESTIMATED)
- **Last updated:** 2020-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04540185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04540185, "A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT04540185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*